Moleculin Biotech Inc. announced that an independent assessment has confirmed the absence of cardiotoxicity in 90 subjects treated with Annamycin, a next-generation anthracycline, across five clinical trials. The reviewed data included subjects with acute myeloid leukemia (AML) and soft tissue sarcoma (STS) treated with Annamycin as monotherapy and in combination with cytarabine at multiple sites in the United States and European Union. The assessment, conducted by an expert affiliated with a leading cancer research institute, found no evidence of cardiotoxicity based on serial ECGs, echocardiography, and cardiac biomarker analysis. Most subjects received doses above the FDA-recommended lifetime maximum for other anthracyclines. These results have already been assessed and reported by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623413-en) on January 13, 2026, and is solely responsible for the information contained therein.